Vergoeding 2019-2023 voor ATC-subgroep A10AE : Langwerkende insulines voor injectie
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| A10AE04 Insuline glargine (Lantus ®) | 41.164.100 | 39.615.900 | 34.040.400 | 34.788.500 | 34.199.900 |
| A10AE05 Insuline detemir (Levemir ®) | 10.395.100 | 8.990.100 | 7.405.700 | 7.083.700 | 6.287.800 |
| A10AE06 Insuline degludec (Tresiba ®) | 19.282.400 | 19.560.200 | 19.769.600 | 21.697.200 | 21.848.900 |
| A10AE54 Insuline glargine met lixisenatide (Suliqua ®) | 657.230 | 452.150 | 346.850 | 262.030 | 216.530 |
| A10AE56 Insuline degludec met liraglutide (Xultophy ®) | 3.521.700 | 2.864.800 | 2.210.500 | 1.913.900 | 1.724.900 |
| Totaal | 75.020.530 | 71.483.150 | 63.773.050 | 65.745.330 | 64.278.030 |